492 related articles for article (PubMed ID: 20675696)
21. Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma.
Armeanu S; Krusch M; Baltz KM; Weiss TS; Smirnow I; Steinle A; Lauer UM; Bitzer M; Salih HR
Clin Cancer Res; 2008 Jun; 14(11):3520-8. PubMed ID: 18519785
[TBL] [Abstract][Full Text] [Related]
22. Oncolytic adenovirus-mediated shRNA against Apollon inhibits tumor cell growth and enhances antitumor effect of 5-fluorouracil.
Chu L; Gu J; Sun L; Qian Q; Qian C; Liu X
Gene Ther; 2008 Apr; 15(7):484-94. PubMed ID: 18239605
[TBL] [Abstract][Full Text] [Related]
23. Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib.
Kardosh A; Golden EB; Pyrko P; Uddin J; Hofman FM; Chen TC; Louie SG; Petasis NA; Schönthal AH
Cancer Res; 2008 Feb; 68(3):843-51. PubMed ID: 18245486
[TBL] [Abstract][Full Text] [Related]
24. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice.
Pei Z; Chu L; Zou W; Zhang Z; Qiu S; Qi R; Gu J; Qian C; Liu X
Hepatology; 2004 May; 39(5):1371-81. PubMed ID: 15122766
[TBL] [Abstract][Full Text] [Related]
25. VSV virotherapy improves chemotherapy by triggering apoptosis due to proteasomal degradation of Mcl-1.
Schache P; Gürlevik E; Strüver N; Woller N; Malek N; Zender L; Manns M; Wirth T; Kühnel F; Kubicka S
Gene Ther; 2009 Jul; 16(7):849-61. PubMed ID: 19369968
[TBL] [Abstract][Full Text] [Related]
26. Proteasome inhibition by bortezomib does not translate into efficacy on two malignant glioma xenografts.
Labussiere M; Pinel S; Delfortrie S; Plenat F; Chastagner P
Oncol Rep; 2008 Nov; 20(5):1283-7. PubMed ID: 18949434
[TBL] [Abstract][Full Text] [Related]
27. A hypoxia- and {alpha}-fetoprotein-dependent oncolytic adenovirus exhibits specific killing of hepatocellular carcinomas.
Kwon OJ; Kim PH; Huyn S; Wu L; Kim M; Yun CO
Clin Cancer Res; 2010 Dec; 16(24):6071-82. PubMed ID: 21169258
[TBL] [Abstract][Full Text] [Related]
28. ADP-overexpressing adenovirus elicits enhanced cytopathic effect by induction of apoptosis.
Yun CO; Kim E; Koo T; Kim H; Lee YS; Kim JH
Cancer Gene Ther; 2005 Jan; 12(1):61-71. PubMed ID: 15375379
[TBL] [Abstract][Full Text] [Related]
29. Effects of bortezomib on human neuroblastoma cells in vitro and in a metastatic xenograft model.
Valentiner U; Haane C; Nehmann N; Schumacher U
Anticancer Res; 2009 Apr; 29(4):1219-25. PubMed ID: 19414367
[TBL] [Abstract][Full Text] [Related]
30. Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model.
El-Shemi AG; Ashshi AM; Na Y; Li Y; Basalamah M; Al-Allaf FA; Oh E; Jung BK; Yun CO
J Exp Clin Cancer Res; 2016 May; 35():74. PubMed ID: 27154307
[TBL] [Abstract][Full Text] [Related]
31. Dual induction of PKR with E2F-1 and IFN-alpha to enhance gene therapy against hepatocellular carcinoma.
Roh V; Laemmle A; Von Holzen U; Stroka D; Dufour JF; Hunt KK; Candinas D; Vorburger SA
Cancer Gene Ther; 2008 Oct; 15(10):636-44. PubMed ID: 18535617
[TBL] [Abstract][Full Text] [Related]
32. Telomerase-dependent virotherapy overcomes resistance of hepatocellular carcinomas against chemotherapy and tumor necrosis factor-related apoptosis-inducing ligand by elimination of Mcl-1.
Wirth T; Kühnel F; Fleischmann-Mundt B; Woller N; Djojosubroto M; Rudolph KL; Manns M; Zender L; Kubicka S
Cancer Res; 2005 Aug; 65(16):7393-402. PubMed ID: 16103092
[TBL] [Abstract][Full Text] [Related]
33. Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma.
Mizukoshi E; Nakamoto Y; Marukawa Y; Arai K; Yamashita T; Tsuji H; Kuzushima K; Takiguchi M; Kaneko S
Hepatology; 2006 Jun; 43(6):1284-94. PubMed ID: 16729333
[TBL] [Abstract][Full Text] [Related]
34. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus.
Diaconu I; Cerullo V; Hirvinen ML; Escutenaire S; Ugolini M; Pesonen SK; Bramante S; Parviainen S; Kanerva A; Loskog AS; Eliopoulos AG; Pesonen S; Hemminki A
Cancer Res; 2012 May; 72(9):2327-38. PubMed ID: 22396493
[TBL] [Abstract][Full Text] [Related]
35. [Cytotoxic effect of oncolytic virus combined with mitomycin against human bladder cancer cells in vitro and in vivo].
Zhao GZ; Tan WL; Zheng SB; Wu YD; Xie Y; Zhu WH
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Nov; 26(11):1623-5, 1628. PubMed ID: 17121717
[TBL] [Abstract][Full Text] [Related]
36. Antitumor effects of telomelysin in combination with paclitaxel or cisplatin on head and neck squamous cell carcinoma.
Kondo N; Tsukuda M; Kimura M; Fujita K; Sakakibara A; Takahashi H; Ishiguro Y; Toth G; Matsuda H
Oncol Rep; 2010 Feb; 23(2):355-63. PubMed ID: 20043095
[TBL] [Abstract][Full Text] [Related]
37. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
[TBL] [Abstract][Full Text] [Related]
38. An armed oncolytic adenovirus ZD55-IL-24 combined with ADM or DDP demonstrated enhanced antitumor effect in lung cancer.
Zhong S; Yu D; Wang Y; Qiu S; Wu S; Liu XY
Acta Oncol; 2010; 49(1):91-9. PubMed ID: 19734998
[TBL] [Abstract][Full Text] [Related]
39. The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response.
Pagnan G; Di Paolo D; Carosio R; Pastorino F; Marimpietri D; Brignole C; Pezzolo A; Loi M; Galietta LJ; Piccardi F; Cilli M; Nico B; Ribatti D; Pistoia V; Ponzoni M
Clin Cancer Res; 2009 Feb; 15(4):1199-209. PubMed ID: 19228726
[TBL] [Abstract][Full Text] [Related]
40. Cyclooxygenase-2 inhibitor and interferon-beta synergistically induce apoptosis in human hepatoma cells in vitro and in vivo.
Nakamoto N; Higuchi H; Kanamori H; Kurita S; Tada S; Takaishi H; Toda K; Yamada T; Kumagai N; Saito H; Hibi T
Int J Oncol; 2006 Sep; 29(3):625-35. PubMed ID: 16865278
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
